Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Adv Cancer Res ; 164: 283-309, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39306368

RESUMEN

Older adults with cancer are at risk of over-treatment or under-treatment, and treatment decision-making is difficult due to both the complexity of adverse aging and under-representation in clinical trials. It is recommended to perform a frailty assessment before treatment decision-making. Although the importance of radiotherapy increases in geriatric oncology, there is less evidence base information on frailty assessment in radiation oncology than in medical/surgical oncology. The present literature review analyzed the available data regarding frailty assessment tools in geriatric radiation oncology. The predictive value of geriatric assessment on survival outcomes has been shown in many cancer subtypes treated with radiotherapy. Additionally, the Geriatric-8 score is the most evidenced screening tool in frailty assessment. However, researches are ongoing on the cut-off points of geriatric screening tools and which one is the best. Prospective randomized controlled trials are required for the integration of geriatric screening tools and geriatric assessment-driven interventions into geriatric radiation oncology practice.


Asunto(s)
Fragilidad , Evaluación Geriátrica , Neoplasias , Oncología por Radiación , Humanos , Evaluación Geriátrica/métodos , Fragilidad/diagnóstico , Oncología por Radiación/métodos , Anciano , Neoplasias/radioterapia , Anciano Frágil , Anciano de 80 o más Años
2.
Technol Cancer Res Treat ; 23: 15330338241280433, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-39196647

RESUMEN

Inflammation plays an important role in the process of cancer development. The number of studies evaluating the ability of inflammatory biomarkers to predict survival has increased in recent years. This study aimed to comprehensively evaluate the predictive role of inflammatory biomarkers in patients with larynx cancer undergoing definitive radiotherapy. A total of 101 patients who underwent definitive radiotherapy for larynx cancer at our center were retrospectively examined. Blood samples were taken from the patients before radiotherapy to obtain biomarkers such as C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), monocyte-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), pan-immune inflammatory value (PIV), hemo-eosinophil inflammation index (HEI), albumin, and Lactate dehydrogenase (LDH). The study examined the predictive value of parameters for progression-free survival (PFS), local recurrence-free survival (LRFS), and overall survival (OS) using both univariate and multivariate Cox regression analysis. In the univariate analysis, the biomarkers that predicted PFS were SII, PIV, CRP, and Eastern Cooperative Oncology Group Performance Status (ECOG PS). According to the multivariate analysis, only CRP was found to be a significant predictor of PFS. In the univariate analysis, the following biomarkers were found to predict OS: NLR, PLR, MLR, SII, PIV, CRP, HEI, stage, and ECOG PS. In the multivariate analysis, NLR and ECOG PS were found to be predictors of OS. A significant difference was found in MLR, PIV, and CRP values based on the presence of lymphatic metastasis. The current study is the first to comprehensively examine the relationship between larynx cancer and several inflammatory biomarkers. Many of these biomarkers have been shown to predict both PFS and OS in patients with larynx cancer undergoing definitive radiotherapy. It has been shown that PIV and CRP may predict the presence of lymphatic metastases in addition to PFS and OS.


Asunto(s)
Biomarcadores de Tumor , Inflamación , Neoplasias Laríngeas , Humanos , Neoplasias Laríngeas/radioterapia , Neoplasias Laríngeas/sangre , Neoplasias Laríngeas/patología , Neoplasias Laríngeas/mortalidad , Masculino , Femenino , Persona de Mediana Edad , Biomarcadores de Tumor/sangre , Anciano , Pronóstico , Inflamación/sangre , Adulto , Estudios Retrospectivos , Neutrófilos/patología , Proteína C-Reactiva/metabolismo , Linfocitos/patología , Anciano de 80 o más Años
3.
Technol Cancer Res Treat ; 23: 15330338241260646, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38841792

RESUMEN

OBJECTIVE: The purpose of this research was to compare two treatment techniques for oropharyngeal cancers: conventional linac-based static intensity-modulated radiotherapy (sIMRT) and helical tomotherapy (HT). The study examined several parameters, including target coverage, organs at risk, integral dose, and beam on time. Additionally, the study evaluated the doses to the parotid, temporomandibular joint, and pharyngeal constrictor muscles, which are important for swallowing. METHOD: The present study retrospectively analyzed the data of 13 patients with oropharyngeal cancer who underwent radiotherapy between 2019 and 2021. The treatment plans for each patient were regenerated using both sIMRT and HT treatment planning systems with the sequential boost method. The techniques were evaluated and compared based on dose-volume histogram, homogeneity index, and conformity index parameters. The target coverage and organs at risk were statistically compared for two techniques. Additionally, the doses received by the healthy tissue volume were obtained for integral dose evaluation. The beam on time for each technique was assessed. RESULTS: When considering planning target volume evaluation, there was no difference in Dmeans between the two techniques and sIMRT demonstrated higher D2% values compared to the HT. The HT technique had better results for all organs at risk, such as the parotid, temporomandibular joint, and pharyngeal constrictor muscle. As for integral dose, it has been shown that the sIMRT technique provides better protection compared to HT. In addition, the beam on time was also longer with the HT technique. CONCLUSION: Both techniques may provide optimal target coverage for patients with oropharyngeal cancer. HT conferred notable advantages, especially with regard to critical structures implicated in swallowing, such as the parotid, temporomandibular joint, and pharyngeal constrictor muscle, in comparison to sIMRT.


Asunto(s)
Órganos en Riesgo , Neoplasias Orofaríngeas , Glándula Parótida , Músculos Faríngeos , Dosificación Radioterapéutica , Planificación de la Radioterapia Asistida por Computador , Radioterapia de Intensidad Modulada , Articulación Temporomandibular , Humanos , Neoplasias Orofaríngeas/radioterapia , Glándula Parótida/efectos de la radiación , Órganos en Riesgo/efectos de la radiación , Planificación de la Radioterapia Asistida por Computador/métodos , Radioterapia de Intensidad Modulada/métodos , Articulación Temporomandibular/efectos de la radiación , Masculino , Estudios Retrospectivos , Músculos Faríngeos/efectos de la radiación , Femenino , Anciano , Persona de Mediana Edad
4.
J Cancer Res Ther ; 18(6): 1823-1826, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-36412455

RESUMEN

Parameningeal rhabdomyosarcomas (PM RMSs) are rarely seen childhood tumors. Their treatment might be challenging and prognosis is poor compared to other head and neck RMS. Here we report a PM RMS presenting with leptomeningeal seeding metastasis a year after diagnosis. A five-year-old girl presented with an enlarging mass protruding from the right ear and right facial paralysis. Magnetic resonance imaging (MRI) revealed a large mass extending from right external auditory canal to the temporal lobe, pterygoid fossa and nasopharynx with an intracranial component indenting the right temporal lobe and extending into the right cavernous sinus. Trucut biopsy revealed embryonal rhabdomyosarcoma. Cerebrospinal fluid (CSF) cytology was negative for malignant cells. Chemotherapy was started since it was found unresectable. At second week of chemotherapy, radiotherapy was applied to primary tumor location with intensity-modulated radiation therapy (IMRT) technique in 1.8 Gy fractions to total dose of 50.4 Gy. At week 27, MRI showed significant response. At week 36, the patient presented with vomiting and tendency to sleep. MRI was found to be compatible with meningitis and antibacterial therapy was started. At week 39, chemotherapy was stopped. But MRI performed one month later revealed linear contrast enhancements around the spinal cord compatible with leptomeningeal metastases. Chemotherapy and craniospinal irradiation were applied. But the patient did not improve and received palliative treatment. Six months after the completion of radiotherapy the patient died. Treatment of parameningeal rhabdomyosarcomas require multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Prognosis is poor for patients with leptomeningeal spread.


Asunto(s)
Carcinomatosis Meníngea , Rabdomiosarcoma Embrionario , Rabdomiosarcoma , Femenino , Humanos , Niño , Preescolar , Rabdomiosarcoma/terapia , Meninges , Imagen por Resonancia Magnética
6.
Strahlenther Onkol ; 198(7): 648-653, 2022 07.
Artículo en Inglés | MEDLINE | ID: mdl-35278096

RESUMEN

PURPOSE: This study aimed to evaluate the therapeutic effect of radiotherapy and to determine possible prognostic factors in patients with painful vertebral hemangioma. METHODS: In the last two decades, 80 patients with vertebral hemangioma who received radiotherapy in our institute were evaluated in terms of pain response, treatment-related side effects, and prognostic factors. All patients were questioned 3 months after radiotherapy for the evaluation of pain response and were divided into three groups (complete response, partial response, and no change). Moreover, the visual analog scale (VAS) was used for pain response assessment in 46 patients. Pain status was assessed to detect recurrence at each clinical examination during the follow-up period. Possible prognostic factors such as gender, size of the hemangioma, location, multilevel involvement and additional musculoskeletal disease on pain response were analyzed. RESULTS: In this study, 45 individuals had lesions in the lumbar spine, 28 in the thoracic, and 7 in the cervical region. Furthermore, 51 patients had additional musculoskeletal conditions such as disc herniation, degenerative diseases, spondylolisthesis, and compression fracture. Radiotherapy was performed with a median daily dose of 2 Gy and a median total dose of 40 Gy. Complete pain response occurred in 58.8% of patients, 26.2% of patients had partial pain response, and 15% of patients had no pain response. The overall response rate was 85%, and 7 patients showed recurrent pain symptoms in the overall response group at routine follow-up. Additional musculoskeletal disorders were found to be the only prognostic factor associated with pain response. The median follow-up time was 60 months. Secondary malignancy was not found in any of the patients in this short follow-up time. No acute or late radiation-associated side effects greater than grade II were observed. CONCLUSION: To our best knowledge, this study is one of the largest single-institution radiotherapy series on vertebral hemangiomas reported to date. The obtained data support the efficacy and safety of radiotherapy in the treatment of painful vertebral hemangioma. Our study showed that additional musculoskeletal disease plays an important role in pain response. Other prognostic factors and treatment of vertebral hemangioma with stereotactic radiosurgery should be investigated in future studies.


Asunto(s)
Hemangioma , Neoplasias de la Columna Vertebral , Hemangioma/complicaciones , Hemangioma/radioterapia , Hemangioma/cirugía , Humanos , Dolor , Dimensión del Dolor , Estudios Retrospectivos , Neoplasias de la Columna Vertebral/radioterapia , Neoplasias de la Columna Vertebral/cirugía , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA